Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: Recent advances and future perspectives
Open Access
- 1 January 2008
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 14 (16) , 2461-2473
- https://doi.org/10.3748/wjg.14.2461
Abstract
Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: Recent advances and future perspectivesKeywords
This publication has 155 references indexed in Scilit:
- Gastrointestinal stromal tumourThe Lancet, 2007
- Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression‐free survival among patients with low‐grade neuroendocrine tumorsCancer, 2007
- Disrupting insulin-like growth factor signaling as a potential cancer therapyMolecular Cancer Therapeutics, 2007
- A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomasBritish Journal of Cancer, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Autocrine growth inhibition by transforming growth factor -1 (TGF -1) in human neuroendocrine tumour cellsGut, 2003
- Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor ReceptorPublished by Elsevier ,2002
- Mutations of the BRAF gene in human cancerNature, 2002
- Intracellular Transactivation of the Insulin-like Growth Factor I Receptor by an Epidermal Growth Factor ReceptorExperimental Cell Research, 1996
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971